M

Miami Dade Medical Research Institute | Miami, FL

Research site
(Unclaimed)
Location
8955 SW 87th Court, Suite 112, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Bryostatin
MGL-3196
DSC127
AVP-786
TRx0237
Troriluzule
Orforglipron
Rocatinlimab
Donanemab
Metformin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 45 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

The co-primary objectives of the study are to:* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Inve...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of mo...

Active, not recruiting
Allergic Contact Dermatitis
Drug: EB01 Cream 2.0%
Drug: EB01 Cream Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.

Enrolling
Attention Deficit Hyperactivity Disorder Combined
Attention Deficit Hyperactivity Disorder
Drug: CTx-1301 - Dexmethylphenidate 31.25mg
Drug: CTx-1301 - Dexmethylphenidate 37.5mg

This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Pe...

Not yet enrolling
Diabetic Foot Ulcers
Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Recently updated

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting
Alzheimer's Disease
Drug: Piromelatine 20 mg
Drug: Placebo

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

Trial sponsors

Madrigal Pharmaceuticals logo
Pfizer logo
BioNTech logo
Biohaven logo
G
Integra LifeSciences logo
LG Chem logo
Lilly logo
N
Otsuka logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems